These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10848652)

  • 1. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection.
    Ohning GV; Barbuti RC; Kovacs TO; Sytnik B; Humphries TJ; Walsh JH
    Aliment Pharmacol Ther; 2000 Jun; 14(6):701-8. PubMed ID: 10848652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).
    Lew EA; Barbuti RC; Kovacs TO; Sytnic B; Humphries TJ; Walsh JH
    Aliment Pharmacol Ther; 1998 Jul; 12(7):667-72. PubMed ID: 9701531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects.
    Ohning GV; Walsh JH; Pisegna JR; Murthy A; Barth J; Kovacs TO
    Aliment Pharmacol Ther; 2003 May; 17(9):1109-14. PubMed ID: 12752347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
    Williams MP; Sercombe J; Hamilton MI; Pounder RE
    Aliment Pharmacol Ther; 1998 Nov; 12(11):1079-89. PubMed ID: 9845397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects.
    Williams MP; Blanshard C; Millson C; Sercombe J; Pounder RE
    Aliment Pharmacol Ther; 2000 Jun; 14(6):691-9. PubMed ID: 10848651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects.
    Bruley des Varannes S; Gharib H; Bicheler V; Bost R; Bonaz B; Stanescu L; Delchier JC; Bonnot-Marlier S
    Aliment Pharmacol Ther; 2004 Oct; 20(8):899-907. PubMed ID: 15479362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
    Williams MP; Usselmann B; Chilton A; Sercombe J; Nwokolo CU; Pounder RE
    Aliment Pharmacol Ther; 2003 Mar; 17(6):775-83. PubMed ID: 12641499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers.
    Dammann HG; Burkhardt F; Wolf N
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1195-203. PubMed ID: 10468701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicobacter pylori infection influences nocturnal gastric acid breakthrough.
    Katsube T; Adachi K; Kawamura A; Amano K; Uchida Y; Watanabe M; Kinoshita Y
    Aliment Pharmacol Ther; 2000 Aug; 14(8):1049-56. PubMed ID: 10930899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
    Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens.
    Adachi K; Komazawa Y; Fujishiro H; Mihara T; Ono M; Yuki M; Kawamura A; Karim Rumi MA; Amano Y; Kinoshita Y
    J Gastroenterol; 2003; 38(9):830-5. PubMed ID: 14564627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects.
    Koop H; Kuly S; Flüg M; Eissele R; Mönnikes H; Rose K; Lühmann R; Schneider A; Fischer R; Arnold R
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):915-8. PubMed ID: 8889461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: the pharmacology of rabeprazole.
    Williams MP; Pounder RE
    Aliment Pharmacol Ther; 1999 Aug; 13 Suppl 3():3-10. PubMed ID: 10491723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
    Cloud ML; Enas N; Humphries TJ; Bassion S
    Dig Dis Sci; 1998 May; 43(5):993-1000. PubMed ID: 9590413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
    Rindi G; Fiocca R; Morocutti A; Jacobs A; Miller N; Thjodleifsson B;
    Eur J Gastroenterol Hepatol; 2005 May; 17(5):559-66. PubMed ID: 15827447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI; Goa KL
    Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy.
    Wang HH; Chou JW; Liao KF; Lin ZY; Lai HC; Hsu CH; Chen CB
    World J Gastroenterol; 2005 Mar; 11(11):1680-4. PubMed ID: 15786549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
    Inamori M; Togawa J; Takahashi K; Yoneda M; Fujisawa N; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
    J Gastroenterol Hepatol; 2003 Sep; 18(9):1034-8. PubMed ID: 12911659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD; Markham A
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects.
    Geus WP; Mulder PG; Nicolai JJ; Van den Boomgaard DM; Lamers CB
    Aliment Pharmacol Ther; 1998 Apr; 12(4):329-35. PubMed ID: 9690721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.